1Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci Met al (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372: 2481–2498. Doi 10.1056/NEJMoa1402121
2Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SMet al (2016) Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164: 550–563. Doi 10.1016/j.cell.2015.12.028
3Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IVet al (2015) Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 372: 2499–2508. Doi 10.1056/NEJMoa1407279
4Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131: 803–820. Doi 10.1007/s00401–016–1545–1
5Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro Aet al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51: 202–206. Doi 10.1038/s41588–018–0312–8
6Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn Met al (2018) Pan-tumor genomic biomarkers for PD–1 checkpoint blockade-based immunotherapy. Science 362. Doi 10.1126/science.aar3593
7Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin Aet al (2018) Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. J Clin Oncol: JCO2018781963. Doi 10.1200/JCO.2018.78.1963
8Hwang WL, Wolfson RL, Niemierko A, Marcus KJ, DuBois SG, Haas-Kogan D (2018) Clinical Impact of Tumor Mutational Burden in Neuroblastoma. J Natl Cancer Inst. Doi 10.1093/jnci/djy157
9Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki Jet al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9: 34. Doi 10.1186/s13073–017–0424–2
10Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya Set al (2016) Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov 6: 1230–1236. Doi 10.1158/2159–8290.CD–16–0575
11Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman Net al (2018) Molecular Determinants of Response to Anti-Programmed Cell Death (PD)–1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol 36: 633–641. Doi 10.1200/JCO.2017.75.3384
12Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale ALet al (2013) Signatures of mutational processes in human cancer. Nature 500: 415–421. Doi 10.1038/nature12477
13Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348: 69–74. Doi 10.1126/science.aaa4971
14Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WWet al (2017) Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol 19: 1047–1057. Doi 10.1093/neuonc/nox026
15Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson Eet al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401–404. Doi 10.1158/2159–8290.CD–12–0095
16Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson Eet al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1. Doi 10.1126/scisignal.2004088
17Bowman RL, Wang Q, Carro A, Verhaak RG, Squatrito M (2017) GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol 19: 139–141. Doi 10.1093/neuonc/now247
18Nakken S, Fournous G, Vodak D, Aasheim LB, Myklebost O, Hovig E (2018) Personal Cancer Genome Reporter: variant interpretation report for precision oncology. Bioinformatics 34: 1778–1780. Doi 10.1093/bioinformatics/btx817
19Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ESet al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550. Doi 10.1073/pnas.0506580102
20Merico D, Isserlin R, Stueker O, Emili A, Bader GD (2010) Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 5: e13984. Doi 10.1371/journal.pone.0013984
21Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MAet al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502: 333–339. Doi 10.1038/nature12634
22Draaisma K, Wijnenga MM, Weenink B, Gao Y, Smid M, Robe P, van den Bent MJ, French PJ (2015) PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathol Commun 3: 88. Doi 10.1186/s40478–015–0265–4
23Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano Eet al (2013) Anti-PD–1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86: 343–349. Doi 10.1016/j.ijrobp.2012.12.025
24Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy Vet al (2016) Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol 34: 2206–2211. Doi 10.1200/JCO.2016.66.6552
25Filley AC, Henriquez M, Dey M (2017) Recurrent glioma clinical trial, CheckMate–143: the game is not over yet. Oncotarget 8: 91779–91794. Doi 10.18632/oncotarget.21586
26Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CMet al (2019) Neoadjuvant anti-PD–1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. Doi 10.1038/s41591–018–0337–7
27Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, Lopez-Janeiro A, Porciuncula A, Idoate MA, Inoges S, de Andrea C, Lopez-Diaz de Cerio A, Tejada Set al (2019) Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. Doi 10.1038/s41591–018–0339–5